# Good-first: B/F/TAF As First-line ART

> **NCT06619288** · — · RECRUITING · sponsor: **Affiliated Hospital of Nantong University** · enrollment: 630 (estimated)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** B/F/TAF
- **DRUG:** TDF+3TC+EFV
- **DRUG:** DTG/3TC

## Key facts

- **NCT ID:** NCT06619288
- **Lead sponsor:** Affiliated Hospital of Nantong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 630 (ESTIMATED)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06619288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06619288, "Good-first: B/F/TAF As First-line ART". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06619288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*